MAPT (Ab-534/217) Antibody

What is the MAPT (Ab-534/217) Antibody and what epitope does it recognize?

The MAPT (Ab-534/217) Antibody is a rabbit polyclonal antibody that specifically recognizes the phosphorylation site at threonine 534/217 of the human Tau protein. The immunogen used is a synthesized non-phosphopeptide derived from Human Tau around the phosphorylation site with the sequence L-P-T(p)-P-P . This antibody is designed to detect endogenous levels of total Tau protein and is particularly useful in detecting phosphorylated Tau, which is implicated in several neurodegenerative disorders .

What are the primary applications for this antibody?

The primary applications for the MAPT (Ab-534/217) Antibody include:

• Western Blot (WB) at recommended dilutions of 1:500-1:3000

• Enzyme-Linked Immunosorbent Assay (ELISA)

The antibody has been validated primarily for Western blot applications, with demonstrated activity in detecting phosphorylated Tau in rat brain extracts .

Which species does this antibody react with?

According to manufacturer specifications, this antibody reacts with:

• Human

• Mouse

• Rat

Most validation data available shows specific testing in rat brain tissue , making it particularly useful for rodent model research of tauopathies.

What are the optimal conditions for using this antibody in Western blot applications?

For optimal Western blot results with the MAPT (Ab-534/217) Antibody:

• Sample preparation: Brain tissue lysates are the recommended positive control, particularly rat brain extracts .

• Dilution range: Use at 1:500-1:3000 dilution depending on signal strength needed .

• Blocking: Standard blocking protocols with BSA or non-fat milk are compatible with this antibody.

• Controls: Use the synthesized peptide as a blocking control to demonstrate specificity, as shown in validation images where the right lane is blocked with the phospho peptide .

• Detection: Standard secondary anti-rabbit IgG antibodies conjugated to HRP, AP, fluorescent labels, or biotin can be used .

How should this antibody be stored to maintain optimal activity?

For proper storage of the MAPT (Ab-534/217) Antibody:

• Store at -20°C upon receipt

• Avoid repeated freeze-thaw cycles

• The antibody is provided in a buffer containing phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol

• Small volumes may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial to dislodge any liquid in the container's cap

How does this antibody contribute to research on tauopathies and Alzheimer's disease?

The MAPT (Ab-534/217) Antibody is particularly valuable for tauopathy research because:

• Pathological significance: Tau phosphorylation at specific sites, including threonine 534/217, is associated with the formation of neurofibrillary tangles, a hallmark of Alzheimer's disease and other tauopathies .

• Disease specificity: MAPT gene mutations have been associated with several neurodegenerative disorders including Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration, and progressive supranuclear palsy .

• Cellular function insight: The antibody helps researchers study how phosphorylation affects Tau's normal function in promoting microtubule assembly and stability, which is crucial for understanding disease mechanisms .

• Structural changes: Detecting phosphorylated Tau can help researchers examine how structural changes in Tau contribute to its pathological aggregation in neurodegenerative disorders .

What considerations should be made when using this antibody to analyze brain tissue from different tauopathy models?

When analyzing different tauopathy models with this antibody:

• Species-specific variations: While the antibody reacts with human, mouse, and rat Tau, there may be differences in phosphorylation patterns across species models. Consider species-specific controls.

• Isoform detection: Human Tau has six isoforms due to alternative splicing, which may be differentially phosphorylated. Mouse and rat models predominantly express 4R Tau isoforms, which may affect interpretation when comparing to human samples .

• Disease stage considerations: Phosphorylation at T534/217 may vary with disease progression. Consider temporal analysis in your experimental design.

• Background staining: In complex tissue samples, validate specificity using blocking peptides as demonstrated in the validation data where peptide-blocked samples show negligible signal .

How can researchers validate the specificity of this antibody?

To validate the specificity of the MAPT (Ab-534/217) Antibody:

• Peptide competition assay: Use the immunogenic peptide to block antibody binding, as shown in validation data where the lane on the right is treated with the synthesized peptide .

• Knockout/knockdown controls: If available, use Tau knockout or knockdown samples as negative controls.

• Phosphatase treatment: Treat samples with phosphatases to remove phosphorylation and confirm the specificity for the phosphorylated form.

• Multiple antibody validation: Compare results with other antibodies targeting different epitopes of Tau to confirm consistency of findings.

What are the common technical issues when working with this antibody and how can they be addressed?

Common technical issues and solutions:

• High background in Western blot:

  • Increase blocking time or concentration of blocking agent

  • Use more stringent washing procedures

  • Optimize antibody dilution (start with 1:1000 and adjust based on results)

  • Consider using different blocking agents (BSA vs. milk)

• Weak or no signal:

  • Confirm sample preparation preserves phosphorylation (use phosphatase inhibitors)

  • Use fresh antibody aliquots to avoid degradation from freeze-thaw cycles

  • Increase antibody concentration or extend incubation time

  • Use enhanced detection systems for low abundance targets

• Multiple bands or unexpected band size:

  • The expected molecular weight of Tau is ~65-80 kDa depending on isoform and phosphorylation state

  • Multiple bands may represent different Tau isoforms or degradation products

  • Optimize sample preparation to minimize proteolysis (use protease inhibitors)

How should experimental designs incorporate controls when using this antibody for studying tau phosphorylation?

Robust experimental design with appropriate controls should include:

• Positive controls: Include rat brain extracts as a reliable positive control .

• Negative controls:

  • Samples treated with lambda phosphatase to remove phosphorylation

  • Primary antibody omission controls

  • Isotype controls to identify non-specific binding

• Peptide competition: Include a condition where the antibody is pre-incubated with the immunogenic peptide to demonstrate specificity .

• Loading controls: Use appropriate housekeeping proteins or total Tau antibodies when studying phosphorylation changes.

• Disease and normal tissue comparisons: Include both pathological and normal samples when studying disease-associated changes in phosphorylation.

How does the phosphorylation at T534/217 relate to tau pathology in different neurodegenerative conditions?

The phosphorylation of Tau at T534/217:

• Pathological significance: This phosphorylation site is among several that are hyperphosphorylated in Alzheimer's disease and other tauopathies, contributing to reduced microtubule binding and increased propensity for aggregation.

• Disease specificity: While hyperphosphorylation is common across tauopathies, different diseases may show distinct phosphorylation patterns. Researchers should consider:

  • Analyzing multiple phosphorylation sites in parallel

  • Correlating T534/217 phosphorylation with clinical and neuropathological features

  • Examining the temporal sequence of phosphorylation events

• Functional implications: The phosphorylation affects the normal function of Tau in promoting microtubule assembly and stability , potentially contributing to neurodegeneration through:

  • Destabilization of microtubules

  • Disruption of axonal transport

  • Altered interactions with neural plasma membrane components

How does the MAPT (Ab-534/217) Antibody compare to other phospho-tau specific antibodies?

When comparing to other phospho-tau antibodies:

• Site specificity: This antibody targets T534/217 specifically, while other commercially available antibodies target different phosphorylation sites like S396/404 (PHF-1), T181 (AT270), or S202/T205 (AT8).

• Research applications: Different phospho-epitopes may be more relevant for specific aspects of tau pathology:

  • Some sites appear earlier in disease progression

  • Others correlate better with clinical severity

  • Select antibodies based on the specific research question

• Cross-reactivity profiles: Each antibody has different cross-reactivity with other phosphorylated proteins, requiring appropriate validation in your experimental system.

What considerations should be made when using multiple tau antibodies in the same study?

When using multiple tau antibodies:

• Sequential analysis: If using the same membrane for multiple antibodies, ensure complete stripping between antibodies or use parallel samples.

• Optimization for each antibody: Each antibody may require different:

  • Dilutions

  • Incubation conditions

  • Detection methods

• Consistent sample preparation: Ensure all samples are prepared identically to allow meaningful comparisons between different antibodies.

• Interpretation of discrepancies: If different tau antibodies give conflicting results:

  • Consider epitope accessibility differences

  • Evaluate isoform specificity

  • Assess phosphorylation state dependencies

How might this antibody be utilized in emerging research on tau propagation and spreading?

The MAPT (Ab-534/217) Antibody could contribute to tau propagation research by:

• Tracking phosphorylated species: Monitor the presence of T534/217 phosphorylated tau in donor and recipient cells in propagation models.

• Characterizing extracellular tau: Determine if secreted or exosomal tau species contain this specific phosphorylation.

• Therapeutic applications: Evaluate whether antibodies targeting this epitope could potentially block tau propagation in cellular or animal models.

• Biomarker development: Assess whether T534/217 phosphorylated tau could serve as a biomarker for disease progression or treatment response.

What are potential applications of this antibody in single-cell analysis techniques?

For single-cell techniques, the antibody could be adapted for:

• Flow cytometry: Optimizing protocols for intracellular phospho-tau detection at the single-cell level.

• Mass cytometry (CyTOF): Metal-conjugated versions of the antibody could enable high-dimensional analysis of tau phosphorylation alongside other cellular markers.

• Single-cell Western blotting: Adapting protocols to detect phospho-tau in individual cells isolated from heterogeneous brain tissue.

• Imaging mass cytometry: Combining with other antibodies to map the spatial distribution of T534/217 phosphorylated tau in relation to other cellular markers in tissue sections.